Abstract
Presentation Description :
With the advent of the first FDA approved gene therapy for eye disease in patients with RPE65-related retinal degeneration, there is increased interest by industry and patients in gene-based therapeutic clinical trials. What are the most promising approaches, and what are the most challenging aspects of gene based therapies? The presentation will provide an overview and update of gene therapy trials for patients with inherited retinal degenerations.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.